Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
Demo Company
GLOBETECH PUBLISHING LLC

Genome Sequencing Enables Discovery of Mutation Leading to Prader-Willi Syndrome, with Link to Autism

By BiotechDaily International staff writers
Posted on 09 Oct 2013
Image: A look inside the human genome-sequencing lab at Complete Genomics (Photo courtesy of Complete Genomics).
Image: A look inside the human genome-sequencing lab at Complete Genomics (Photo courtesy of Complete Genomics).
Highly accurate whole genome sequencing technology has played a pivotal role in identifying a mutation involved in causing Prader-Willi Syndrome, helping to resolve a diagnostic conundrum.

Prader-Willi Syndrome (PWS) is a rare (around 1:15,000) genetic disorder that leads to poor muscle tone, low levels of sex hormones, and a constant feeling of hunger often leading to obesity. It occurs in males and females equally, and affects all races. The whole genome sequencing technology of Complete Genomics, Inc. (Mountain View, CA, USA), subsidiary of BGI-Shenzhen, was used in the identification of a point mutation causing PWS, a discovery that helped resolve a diagnostic conundrum for four young male patients who tested PWS-negative as infants.

The study, published September 29, 2013, in the journal Nature Genetics, is a collaborative effort of researchers at Baylor College of Medicine (BCM; Houston, TX, USA), the Jan and Dan Duncan Neurological Research Institute (Duncan NRI; Houston, TX, USA), and the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (Houston, TX, USA).

The first patient tested PWS negative by age one year, but over the next 12 years began to manifest some of the typical PWS symptoms. Complete Genomics’ sequencing service was used in an analysis determining the genetic basis of his symptoms: a single mutation, a base deletion, was identified in the protein-coding MAGEL2 gene, in a section of chromosome 15 previously linked to PWS, and in a difficult to sequence GC rich region. It proved to be a frame-shift deletion, truncating mutation, which disrupts the MAGEL2 protein product. As MAGEL2 is only known to be expressed from the paternal gene allele (the maternal allele being silenced), it was also important to determine whether the mutation was on the maternal or paternal version of chromosome 15. In this case, the MAGEL2 mutation was confirmed to be on the paternal allele using a modified version of Complete Genomics’ Long Fragment Read technology.

To further investigate MAGEL2’s role in PLW, the researchers reviewed over 1,200 exome sequencing reports, searching for other patients with loss-of-function mutations in that gene. Three additional patients were identified – one with classic PWS, the other two with PWS-like symptoms. However, all had negative PWS tests as infants. All four patients were also diagnosed with autism spectrum disorder (ASD) and intellectual disability. These findings suggest that MAGEL2 is a new gene causing complex ASD and that MAGEL2 loss of function can contribute to several aspects of the PWS phenotype.

“This is the first study to show that point mutations can cause Prader-Willi Syndrome,” said Dr. Schaaf, assistant professor of molecular and human genetics at BCM and faculty member at the Duncan NRI; “This is an important development that increases our understanding of this complex disorder, and also gives four boys a diagnosis, which they and their parents have sought for many years.” “It also underscores the importance of being able to distinguish between maternal and paternal variants because only patients who had point mutations on the paternal copy of the MAGEL2 gene would experience the disorder,” added Dr. Brock Peters, director of research at Complete Genomics.

Related Links:

Complete Genomics
Baylor College of Medicine
The Jan and Dan Duncan Neurological Research Institute (of Texas Children's Hospital)



Channels

Drug Discovery

view channel
Image: Cancer cells were treated with a control (left) and the overstimulating compound MCB-613 (right) (Photo courtesy of Dr. Lei Wang, Baylor University College of Medicine).

Drug Candidate Propels Cancer Cells into Fatal Overdrive

A candidate drug that destroys cancer cells by stimulating them to produce more proteins than the cells can actually process was shown to kill a wide variety of cancer cells in culture and to inhibit tumor... Read more

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

Innovative Microbial Diagnostics Developer Acquired by Biomedical Giant

A biotech company noted for its development of innovative products in the field of molecular microbiology diagnostics has been acquired by one of the world's largest biomedical corporations. GeneWEAVE BioSciences, Inc.(Los Gatos, CA, USA) and Roche (Basel, Switzerland) have announced that Roche will be purchasing the... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.